EU-JAMRAI2, the second edition of the European Joint Action on Antimicrobial Resistance (AMR) and Healthcare-Associated Infections, emerges with the ambitious goal of changing the world’s approach to antimicrobial resistance through a One Health perspective. Building on the success of its inaugural edition (2017-2021), the European Union has made an unprecedented investment in the second edition, EU-JAMRAI 2, firmly believing that collaborative efforts among the union’s 30 member countries will elevate Europe as a beacon of best practices.
General objectives:
- Provide direct and sizable support to help MS in the development and the update of their National Action Plan (NAP) on AMR
- Support the wider uptake of state-of-the-art Infection Prevention Control (IPC) for both community-acquired and healthcare-associated infections, as well as Antimicrobial Stewardship (AMS) strategies in various settings
- Strengthen the responsiveness and coordination of health systems to protect people from AMR in the Union
- Increase awareness and understanding of AMR across Europe
- Promote the One Health approach
- Provide continuity and further uptake of the policy recommendations from EU-JAMRAI 1
- Make Europe a best practice region
More than 120 partners from 30 countries, supported by approximately 40 stakeholders, are actively engaged in this joint action. European institutions such as ECDC and EFSA, alongside global bodies including WHO, WOAH, OECD, UNEP, and FAO, contribute their expertise to enrich discussions and ensure alignment with existing initiatives. Furthermore, professionals in human, animal, and environmental health, as well as patient representatives, play integral roles in this collective effort.
The project is lead b Institut National de la Sante et de la Recherche Medicale, INSERM, France.
Project leader at Norwegian Veterinary Institute: Anne Margrete Urdahl
Read more about EU-JAMRAI
